Mauro Ragonese

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese et al. · BMC Cancer · 2018 · 78 citations · Full text

Is Systemic Immune-Inflammation Index a Real Non-Invasive Biomarker to Predict Oncological Outcomes in Patients Eligible for Radical Cystectomy?

Pierluigi Russo, Filippo Marino, Francesco Rossi et al. · Medicina · 2023 · 36 citations · Full text

Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?

Marco Racioppi, L. Di Gianfrancesco, Mauro Ragonese et al. · International braz j urol · 2019 · 27 citations · Full text

The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.

Francesco Pierconti, Maurizio Martini, Tonia Cenci et al. · Urologic Oncology Seminars and Original Investigations · 2021 · 25 citations

Urological Research, Urology, Urologic Cancer Epidemiology +7

SIRI as a biomarker for bladder neoplasm: Utilizing decision curve analysis to evaluate clinical net benefit

Pierluigi Russo, Nazario Foschi, Giuseppe Palermo et al. · Urologic Oncology Seminars and Original Investigations · 2025 · 24 citations · Full text